Infection by Streptococcus pneumoniae, which can result in development of pneumonia, meningitis, sepsis and bacteraemia, is a leading cause of ill-health and death in children, elderly and immunocompromised worldwide. The high prevalence of antimicrobial resistant pneumococci has prompted further emphasis on the importance of pneumococcal vaccines. There are over 95 serotypes, and current licenced vaccines, based on capsular components, only protect against 13. These vaccines are expensive to produce which limits the affordability and availability, especially in low and middle-income countries where the burden of the disease is the highest. In addition, there is potential for serotype replacement, which can hinder efforts to control colonisation and the disease.
To address these limitations, we propose a spray dried nanoparticle (NP) vaccine, which incorporates multiple pneumococcal protein antigens, to ensure coverage against multiple strains. The formulation will be administered through the mucosal route in order to induce mucosal immune responses. A mucosally administered pneumococcal vaccine which has complete coverage of serotypes, would not only provide a single vaccine which could be used all over the world, but also offers a needle-free means of administration to promote use. Additionally, the formulation of the vaccine will be prepared using readily available scale-up production methods, addressing a large hurdle in pre-clinical translation and further reducing costs. The dry powder form of the vaccine also addresses accessibility through and negation of cold chain requirements. The project seeks to produce and evaluate spray dried NPs, incorporating pneumococcal protein antigens, as a mucosal vaccine against all pneumococcal serotypes.
Professor Imran Saleem
Professor in Nanomedicine
Liverpool John Moores University (UK)
Dr Viviane Maimoni Gonçalves, Instituto Butantan (Brazil)
Dr Eliane Namie Miyaji, Instituto Butantan (Brazil)
Dr Richard Broadhead, Precision Nanosystems (UK)